Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transition to Chronic Fibrosis in an Animal Model of Retinal Detachment With Features of Proliferative Vitreoretinopathy. | Invest Ophthalmol Vis Sci | 2023 | 38153753 | PubTator, text mining | PubMed |
| Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022). | Front Cell Infect Microbiol | 2023 | 38145048 | PubTator, text mining | PubMed |
| Microneedle-Mediated Transdermal Delivery of Genetic Materials, Stem Cells, and Secretome: An Update and Progression. | Pharmaceutics | 2023 | 38140107 | PubTator, text mining | PubMed |
| Recent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review. | Biomedicines | 2023 | 38137442 | PubTator, text mining | PubMed |
| Frequency and Pattern of Worldwide Ocular Gene Therapy Clinical Trials up to 2022. | Biomedicines | 2023 | 38137345 | PubTator, text mining | PubMed |
| Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina. | Antioxidants (Basel) | 2023 | 38136230 | PubTator, text mining | PubMed |
| The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma. | Invest Ophthalmol Vis Sci | 2023 | 38133505 | PubTator, text mining | PubMed |
| Treatment Strategy With Gene Editing for Late-Onset Retinal Degeneration Caused by a Founder Variant in C1QTNF5. | Invest Ophthalmol Vis Sci | 2023 | 38133503 | PubTator, text mining | PubMed |
| 13th C1-inhibitor deficiency and angioedema workshop-2023 : Edited by: Róbert Hohol; Lectored by: Henriette Farkas, Lilian Varga; Cover artwork: Gergely Hosszú. | Allergy Asthma Clin Immunol | 2023 | 38124188 | PubTator, text mining | PubMed |
| Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. | Ann Med Surg (Lond) | 2023 | 38098608 | PubTator, text mining | PubMed |
| Comparison of retinal degeneration treatment with four types of different mesenchymal stem cells, human induced pluripotent stem cells and RPE cells in a rat retinal degeneration model. | J Transl Med | 2023 | 38098048 | PubTator, text mining | PubMed |
| AAV capsid bioengineering in primary human retina models. | Sci Rep | 2023 | 38081924 | PubTator, text mining | PubMed |
| Patterns of Gene Expression, Splicing, and Allele-Specific Expression Vary among Macular Tissues and Clinical Stages of Age-Related Macular Degeneration. | Cells | 2023 | 38067097 | PubTator, text mining | PubMed |
| An Optical Coherence Tomography-Based Measure as an Independent Estimate of Retinal Function in Retinitis Pigmentosa. | Diagnostics (Basel) | 2023 | 38066762 | PubTator, text mining | PubMed |
| Pathologic vs. protective roles of hypoxia-inducible factor 1 in RPE and photoreceptors in wet vs. dry age-related macular degeneration. | Proc Natl Acad Sci U S A | 2023 | 38055741 | PubTator, text mining | PubMed |
| Update on gene therapies in pediatric ophthalmology. | Arch Pediatr | 2023 | 38043982 | PubTator, text mining | PubMed |
| Retinitis Pigmentosa: Pathogenesis, Diagnostic Findings, and Treatment. | Cureus | 2023 | 38034182 | PubTator, text mining | PubMed |
| Comprehensive Transcriptomic Investigation of Rett Syndrome Reveals Increasing Complexity Trends from Induced Pluripotent Stem Cells to Neurons with Implications for Enriched Pathways. | ACS Omega | 2023 | 38027357 | PubTator, text mining | PubMed |
| Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling. | Drug Des Devel Ther | 2023 | 38024539 | PubTator, text mining | PubMed |
| Application of patient-derived induced pluripotent stem cells and organoids in inherited retinal diseases. | Stem Cell Res Ther | 2023 | 38012786 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=12